TABLE 2.
The role of DOCK2 in diseases.
| Diseases | Main subjects | Mechanisms | Functions | Immune cells involved | References |
|---|---|---|---|---|---|
| Nervous system disease | |||||
| Alzheimer’s disease | In vivo; In vitro | Regulates cytokine secretion, phagocytosis and paracrine neurotoxicity in microglia; Promotes the accumulation of Aβ plaques | Promotes the development of AD. | Microglial | Cimino et al. (2009), Cimino et al. (2013) |
| Stroke | In vivo | Downregulates the expression of p-STAT6, thereby promoting M1 polarization | Aggravates the cerebral ischemia/reperfusion | Microglial | Ding et al. (2022) |
| Respiratory disease | |||||
| Pulmonary fibrosis | In vivo; In vitro | Regulates the TGF-β-mediated MesoMT and FMT processes | Promotes the extent of pulmonary fibrosis | Macrophages | Qian et al. (2022a), Ma et al. (2022b), Qian et al. (2022b), Guo et al. (2022) |
| Acute lung injury | In vivo | Exacerbates inflammatory cell infiltration and increases MPO activity | Promotes the advancement of ALI | Macrophages | Xu et al. (2021) |
| COVID-19 | Human samples; In vivo; In vitro | Regulates macrophages recruitment and IFNs response | Inhibits the progression of COVID-19 | Namkoong et al. (2022) | |
| Lung cancer | Human samples | May excessively activate the MYC and the DNA repair signaling pathways | Promotes the progression of NSCLC | Zeng et al. (2021) | |
| Heart Diseases | |||||
| Myocarditis | In vitro | Reduces t miR-16 expression and upregulates the expression of pro-inflammatory factors | Facilitates the development of myocarditis | Wang et al. (2020) | |
| Digestive system diseases | |||||
| Colitis | In vivo; In vitro | Regulates macrophage’s function and microbial populations bidirectionally | Inhibits the development of colitis | Macrophages | Liu et al. (2016), Ji et al. (2021), Xie et al. (2021) |
| Colorectal cancer | Human sample | Mediates the recruitment of T cells | Inhibits the malignant progression of CRC | Lymphocytes | Yu et al. (2015), Miao et al. (2018), Kadkhoda et al. (2021) |
| Prostate cancer | Human sample; In vitro | Involved in methylation and cell proliferation | Predicts the malignant progression of PCa | El Haibi et al. (2010), El-Haibi et al. (2012), Bjerre et al. (2019), Bjerre et al. (2020) | |
| Hematologic Diseases | |||||
| Chronic lymphocytic Leukemia | Human sample; In vivo; In vitro | Regulates the cell proliferation together with Wnt5a-ROR1 axis | Promotes the progression of CLL | Lymphocytes | Wang et al. (2010), O'Hayre et al. (2010), Hasan et al. (2018) |
| Acute myelocytic leukemia | Human sample; In vivo; In vitro | Regulates the cell proliferation through Rac1-related pathway and sensitivity to drugs | Promotes the development of AML | Lymphocytes | Nishihara et al. (2002), Wu et al. (2017), Hu et al. (2019), Wu et al. (2019) |
| Skin cancer | |||||
| Melanoma | In vivo; In vitro | Assists melanoma stem cells to anti-apoptosis | Contributes to the development of melanoma | Chu et al. (2021), Zhang et al. (2022) | |
| Transplantation Immunology | |||||
| Rejection of heart transplantation | In vivo | Regulates T cell numbers and inflammatory factor levels | Exacerbates graft rejection | Lymphocytes | Jiang et al. (2005) |
| Immune deficiency disease | |||||
| Combined immunodeficiencies | Human sample; In vivo; In vitro | Promotes the growth of T and B cells and ensures the function of NK cells | Maintains normal immune function | Lymphocytes | Alizadeh et al. (2018), Dobbs et al. (2015), Alosaimi et al. (2019), Sharifinejad et al. (2021), Aytekin et al. (2021), D'Astous-Gauthier et al. (2021) |
In vivo represents animal experiments; In vitro represents cell experiments; Human samples represent human sample sections and human related databases.